Compare MakeMyTrip Ltd (MMYT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Merck & Co., Inc. — how do they compare? MakeMyTrip Ltd trades at $60.31 (market cap $5.68B), while Merck & Co., Inc. trades at $133.33 (market cap $327.94B). The key difference: Merck & Co., Inc. is far larger — about 57.7× MakeMyTrip Ltd's market cap, and Merck & Co., Inc. pays a 2.56% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| MMYT | MRK | |
|---|---|---|
Market Cap | $5.68B | $327.94B |
Sector | Technology | Health |
52-Week High | $103.21 | $132.93 |
52-Week Low | $36.30 | $77.60 |
Enterprise Value | $6.34B | $374.70B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.
Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters with Q3 2026 results pending. Revenue grew to $65.01B in 2025 with net income of $18.25B, though 2026 projections show lower profitability. Recent acquisition activity includes the $6.7B tender offer for Terns Pharmaceuticals to bolster oncology pipeline.
Merck maintains solid fundamentals with 67.6% analyst buy ratings and $140.58 consensus target, offering 7.8% upside. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The stock presents a balanced opportunity with strong institutional support but faces margin compression headwinds in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
